One Wealth Advisors LLC Sells 9,296 Shares of Edwards Lifesciences Corporation $EW

Key Points

• One Wealth Advisors LLC sold 9,296 shares of Edwards Lifesciences, reducing its stake by 50.8%, leaving them with 9,008 shares valued at $705,000.
• Several hedge funds increased their positions in Edwards Lifesciences, with 79.46% of the stock currently owned by institutional investors.
• Analysts have increased price targets for Edwards Lifesciences, with consensus rating at "Moderate Buy" and an average price target of $86.61.

One Wealth Advisors LLC lessened its stake in Edwards Lifesciences Corporation (NYSE:EW - Free Report) by 50.8% in the 2nd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 9,008 shares of the medical research company's stock after selling 9,296 shares during the quarter. One Wealth Advisors LLC's holdings in Edwards Lifesciences were worth $705,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also made changes to their positions in the stock. Quantbot Technologies LP acquired a new stake in shares of Edwards Lifesciences in the 1st quarter valued at about $26,000. SouthState Corp bought a new position in shares of Edwards Lifesciences during the first quarter worth about $27,000. Global X Japan Co. Ltd. grew its holdings in shares of Edwards Lifesciences by 116.1% during the first quarter. Global X Japan Co. Ltd. now owns 402 shares of the medical research company's stock worth $29,000 after buying an additional 216 shares in the last quarter. Tradewinds Capital Management LLC raised its position in Edwards Lifesciences by 102.5% in the 1st quarter. Tradewinds Capital Management LLC now owns 405 shares of the medical research company's stock valued at $29,000 after buying an additional 205 shares during the last quarter. Finally, Rossby Financial LCC bought a new stake in Edwards Lifesciences in the 1st quarter valued at approximately $29,000. 79.46% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

EW has been the subject of a number of recent research reports. Wells Fargo & Company upped their price target on Edwards Lifesciences from $84.00 to $88.00 and gave the stock an "overweight" rating in a research report on Thursday, August 7th. Daiwa America upgraded shares of Edwards Lifesciences from a "hold" rating to a "strong-buy" rating in a report on Tuesday, July 29th. The Goldman Sachs Group reaffirmed a "buy" rating on shares of Edwards Lifesciences in a research report on Friday, July 25th. Royal Bank Of Canada lifted their price target on shares of Edwards Lifesciences from $85.00 to $89.00 and gave the company an "outperform" rating in a research note on Friday, July 25th. Finally, Barclays boosted their price target on shares of Edwards Lifesciences from $90.00 to $95.00 and gave the stock an "overweight" rating in a research report on Friday, July 25th. Three investment analysts have rated the stock with a Strong Buy rating, eleven have given a Buy rating, eight have assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, Edwards Lifesciences currently has a consensus rating of "Moderate Buy" and a consensus price target of $86.61.

Insider Buying and Selling

In other Edwards Lifesciences news, insider Larry L. Wood sold 8,950 shares of the firm's stock in a transaction on Monday, August 18th. The stock was sold at an average price of $78.06, for a total transaction of $698,637.00. Following the completion of the sale, the insider owned 206,900 shares of the company's stock, valued at $16,150,614. This trade represents a 4.15% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, VP Daniel J. Lippis sold 4,114 shares of the firm's stock in a transaction dated Monday, July 28th. The stock was sold at an average price of $79.46, for a total transaction of $326,898.44. Following the sale, the vice president owned 22,002 shares of the company's stock, valued at approximately $1,748,278.92. This represents a 15.75% decrease in their position. The disclosure for this sale can be found here. Company insiders own 0.34% of the company's stock.

Edwards Lifesciences Stock Performance

NYSE EW opened at $77.25 on Tuesday. The firm has a market capitalization of $45.35 billion, a P/E ratio of 11.11, a price-to-earnings-growth ratio of 3.67 and a beta of 1.07. The company has a current ratio of 4.68, a quick ratio of 3.87 and a debt-to-equity ratio of 0.06. The firm's fifty day moving average price is $78.51 and its two-hundred day moving average price is $75.83. Edwards Lifesciences Corporation has a 1 year low of $64.00 and a 1 year high of $83.00.

Edwards Lifesciences (NYSE:EW - Get Free Report) last announced its quarterly earnings data on Thursday, July 24th. The medical research company reported $0.67 EPS for the quarter, beating analysts' consensus estimates of $0.62 by $0.05. The company had revenue of $1.53 billion during the quarter, compared to the consensus estimate of $1.49 billion. Edwards Lifesciences had a net margin of 72.96% and a return on equity of 15.01%. The company's quarterly revenue was up 11.9% on a year-over-year basis. During the same quarter last year, the firm posted $0.70 EPS. Edwards Lifesciences has set its Q3 2025 guidance at 0.540-0.60 EPS. FY 2025 guidance at 2.400-2.500 EPS. As a group, research analysts anticipate that Edwards Lifesciences Corporation will post 2.45 EPS for the current year.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.

Want to see what other hedge funds are holding EW? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Edwards Lifesciences Corporation (NYSE:EW - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.